CR20110032A - Derivados de tiofeno y tiazol y su uso como inhibidores de p13k - Google Patents

Derivados de tiofeno y tiazol y su uso como inhibidores de p13k

Info

Publication number
CR20110032A
CR20110032A CR20110032A CR20110032A CR20110032A CR 20110032 A CR20110032 A CR 20110032A CR 20110032 A CR20110032 A CR 20110032A CR 20110032 A CR20110032 A CR 20110032A CR 20110032 A CR20110032 A CR 20110032A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
tiazol
thiophen
derivatives
inflammatory
Prior art date
Application number
CR20110032A
Other languages
English (en)
Spanish (es)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul D Greenspan
Stepan Vyskocil
Tianlin; Xu
Christelle C Renou
Original Assignee
Millenium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millenium Pharmaceuticals Inc filed Critical Millenium Pharmaceuticals Inc
Publication of CR20110032A publication Critical patent/CR20110032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR20110032A 2008-06-19 2011-01-17 Derivados de tiofeno y tiazol y su uso como inhibidores de p13k CR20110032A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19

Publications (1)

Publication Number Publication Date
CR20110032A true CR20110032A (es) 2011-03-14

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110032A CR20110032A (es) 2008-06-19 2011-01-17 Derivados de tiofeno y tiazol y su uso como inhibidores de p13k

Country Status (21)

Country Link
US (3) US8183240B2 (enExample)
EP (1) EP2313399B1 (enExample)
JP (1) JP5596026B2 (enExample)
KR (1) KR20110018451A (enExample)
CN (1) CN102066365A (enExample)
AU (1) AU2009260782B2 (enExample)
BR (1) BRPI0914223A2 (enExample)
CA (1) CA2727069A1 (enExample)
CL (1) CL2010001474A1 (enExample)
CO (1) CO6331431A2 (enExample)
CR (1) CR20110032A (enExample)
EA (1) EA201170052A1 (enExample)
ES (1) ES2491522T3 (enExample)
GE (1) GEP20125650B (enExample)
IL (1) IL210055A0 (enExample)
MA (1) MA32468B1 (enExample)
MX (1) MX2010014125A (enExample)
NZ (1) NZ589844A (enExample)
UA (1) UA106206C2 (enExample)
WO (1) WO2009154741A1 (enExample)
ZA (1) ZA201008875B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0914223A2 (pt) * 2008-06-19 2019-09-24 Millennium Pharm Inc derivados de tiofeno ou tiazol e seus usos como inibidores de p13k
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
MA34797B1 (fr) * 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
EP2603216A4 (en) * 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
WO2012051410A2 (en) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
JP6117235B2 (ja) 2011-12-15 2017-04-19 ノバルティス アーゲー Ｐｉ３ｋの活性または機能の阻害剤の使用
UY34539A (es) * 2011-12-23 2013-06-28 Millennium Pharm Inc Heteroarilos y usos de los mismos
EP2825889A4 (en) 2012-03-14 2015-10-28 Salk Inst For Biological Studi ADENOVIRAL TUMOR DIAGNOSIS
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
RU2015143437A (ru) 2013-03-15 2017-04-27 Дженентек, Инк. Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
RU2016136091A (ru) * 2014-02-14 2018-03-19 Дзе Юниверсити Оф Бритиш Коламбиа Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
CA3144848C (en) * 2019-06-28 2023-11-21 Pfizer Inc. 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
RU2439074C2 (ru) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
WO2007129044A1 (en) 2006-05-03 2007-11-15 Astrazeneca Ab Thiazole derivatives and their use as anti-tumour agents
JP5534811B2 (ja) * 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
ES2399774T3 (es) * 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
US9029411B2 (en) * 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0914223A2 (pt) * 2008-06-19 2019-09-24 Millennium Pharm Inc derivados de tiofeno ou tiazol e seus usos como inibidores de p13k

Also Published As

Publication number Publication date
EP2313399B1 (en) 2014-05-28
AU2009260782A1 (en) 2009-12-23
WO2009154741A8 (en) 2010-03-25
GEP20125650B (en) 2012-09-25
ES2491522T3 (es) 2014-09-08
CO6331431A2 (es) 2011-10-20
IL210055A0 (en) 2011-02-28
CL2010001474A1 (es) 2011-04-29
NZ589844A (en) 2012-11-30
KR20110018451A (ko) 2011-02-23
EA201170052A1 (ru) 2011-06-30
JP5596026B2 (ja) 2014-09-24
ZA201008875B (en) 2012-02-29
US8440664B2 (en) 2013-05-14
AU2009260782B2 (en) 2014-12-11
BRPI0914223A2 (pt) 2019-09-24
CN102066365A (zh) 2011-05-18
US20130217689A1 (en) 2013-08-22
EP2313399A1 (en) 2011-04-27
WO2009154741A1 (en) 2009-12-23
US20120202812A1 (en) 2012-08-09
US8183240B2 (en) 2012-05-22
UA106206C2 (ru) 2014-08-11
MA32468B1 (fr) 2011-07-03
CA2727069A1 (en) 2009-12-23
US20100075951A1 (en) 2010-03-25
JP2011524904A (ja) 2011-09-08
MX2010014125A (es) 2011-02-24

Similar Documents

Publication Publication Date Title
CO6331431A2 (es) Derivados de tiofeno o tiazol y su uso como inhibidores de p13k
UY33554A (es) Heteroarilos y usos de los mismos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
UY32303A (es) Tiolactamas y sus usos
CL2011002739A1 (es) Compuestos derivados de 3-(1h-pirrolo[2,3-b]piridina-3-carbonil)-bencenosulfonamida; composicion farmaceutica que los comprende; kit; y su uso como inhibidores de raf para el tratamiento de una enfermedad o condicion seleccionada de melanoma, glioma, glioblastoma multiforme, cancer colorrectal, cancer de pulmon, entre otras.
DOP2011000217A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
UY32049A (es) Inhibidores de cmet
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CR11871A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3- dioxigenasa
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
DOP2013000082A (es) Heteroarilos y sus usos
EP2603216A4 (en) HETEROARYLE AND USES THEREOF
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
UY32320A (es) Nuevos compuestos de ciclopentanodiona herbicidamente activos, derivados, procesos, composiciones y uso en el control de malas hierbas
BR112015005562A2 (pt) compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)